Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

INTRODUCTION: Guselkumab, an anti-interleukin-23 biologic therapy, has been shown to significantly reduce disease activity and improve patient-reported outcome measures (PROMs) among patients with moderate-to-severe plaque psoriasis in clinical trials. However, characterization of the real-world eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, April W., Fitzgerald, Timothy, McLean, Robert R., Teeple, Amanda, Uy, Jonathan P., Olurinde, Mobolaji, Rowland, Katelyn, Guo, Lin, Shan, Ying, Callis Duffin, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884731/
https://www.ncbi.nlm.nih.gov/pubmed/36585606
http://dx.doi.org/10.1007/s13555-022-00879-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884731/
https://www.ncbi.nlm.nih.gov/pubmed/36585606
http://dx.doi.org/10.1007/s13555-022-00879-8

Ejemplares similares